RareRx Pulse
A plain-language pipeline tracker for patients and caregivers with rare diseases — get a friendly alert when a candidate targeting your condition appears in clinical pipelines emerging from new AI engines like IsoDDE.
patients with rare diseases and their caregivers tracking research progress
- Personalized alerts when a candidate for your condition enters a public pipeline
- Plain-English progress tracker: pre-clinical → Phase 1 → 2 → 3 → approved
- Glossary that explains binding affinity, cryptic pockets, and induced fit in simple terms
- Community board moderated by medical writers
AI drug discovery just accelerated meaningfully; patients currently have no real-time view of which diseases the new generation of engines is prioritizing, and the lag causes real harm.
Rare disease app market is large and growing ($1.8B in 2025, 13% CAGR per Dataintelo) with active patient/caregiver communities (200k+ at Rare Patient Voice, 11k+ on UniteRare, 10,888+ conditions on Kisho), but most demand concentrates on trial-finding and support, not pipeline tracking.Rare Disease Community App Market Research Report 2034 ↗UniteRare™ — Rare Disease Navigation Platform | Free for Patients ↗
Market is crowded with free AI-mediated competitors: Trial Friend, UniteRare, TrialGPT (Foundation 29), Clifton (GitHub), Know Rare HealthStoryAI, plus OpenAI's ChatGPT Health — all doing plain-language trial discovery.TrialGPT: Find and connect with clinical trials worldwide ↗GitHub - notwopr/clifton: Easy Clinical Trial Tracker ↗Introducing ChatGPT Health - OpenAI ↗
Direct B2C monetization is weak — every named competitor is free, and rare-disease patients overwhelmingly prefer free tools (97% willing to share data per HitLab); viable B2B angle (pharma intent data) requires a different go-to-market than the consumer pitch implies.Trial Friend | Rare Disease Clinical Trials & Treatments ↗From Rare Disease Insights to Complex Care Innovation (MiraKare) ↗
AI drug discovery is genuinely accelerating (IsoDDE more than doubles AlphaFold 3 accuracy, Isomorphic Labs-J&J partnership, multi-year pipeline of novel candidates), and 10,000+ rare conditions remain chronically underserved — sustained demand for years.The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold ↗AI accelerates drug discovery from decades to months as Isomorphic Labs Drug Design Engine pushes beyond Nobel-level science ↗
Trial-tracking half is trivially buildable (ClinicalTrials.gov has free API, open-source NL wrappers like clifton and clinical-trials-patient exist); the differentiated half — surfacing IsoDDE-style engine output in real time — is hard because AI-discovery pipelines are proprietary and disclosed piecemeal via press releases and preprints, requiring constant curation.Clinical Trials Patient: Find Trials with Natural Language ↗Isomorphic Labs & AlphaFold: AI Drug Discovery in Trials ↗